Translating science into clinical practice: Focus on vildagliptin in combination with metformin

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 2, 2009, Pages 18-26

  Barnett, Anthony H ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Clinical practice; Combination therapy; Glycaemic control; Glycated haemoglobin; Metformin; Vildagliptin

Indexed keywords

GALVUSMET; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; METFORMIN PLUS VILDAGLIPTIN; PIOGLITAZONE; PLACEBO; UNCLASSIFIED DRUG; VILDAGLIPTIN;

ABDOMINAL PAIN; ADD ON THERAPY; ASTHENIA; BACKACHE; CLINICAL PRACTICE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; GLYCEMIC CONTROL; HUMAN; HUNGER; HYPERHIDROSIS; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; LIMB PAIN; LOW DRUG DOSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 65449174260     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01030.x     Document Type: Review

References (19)

1. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.
2. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database of Syst Rev 2008; CD006739. doi:10.1002/14651858.CD006739.pub2.
3. Bolli G, Dotta F, Rochotte E, Cohen SE. Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: A 24-week, randomized, double-blind study. Diabetes Obes Metab 2008; 10: 82-90.
4. Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50: 1148-1155.
5. Ahrén B, Landin-Olsson M, Jansson PA et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
6. Balas B, Baig MR, Watson C et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab 2007; 92: 1249-1255.
7. Matikainen N, Mänttäri S, Schweizer A et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49: 2049-2057.
8. Rosenstock J, Foley JE, Rendell M et al. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care 2008; 31: 30-35.
9. Yasuda N, Inoue T, Nagakura T et al. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds. Biochem Biophys Res Commun 2002; 298: 779-784.
10. Hinke SA, Kühn-Wache K, Hoffmann T et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-1308.
11. Migoya EM, Miller JL, Larson PJ et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations. Diabetologia 2008; 51(Suppl. 1): S52. Abstract 0111.
12. Dunning BE, Ligueros-Saylan M, D'Alessio DA et al. Differential effects of DPP-4 inhibition on incretin hormone levels in drug-naive and metformin-treated patients with type 2 diabetes. Diabetologia 2008; 51(Suppl. 1): 110-111. Abstract 0174.
13. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24: 460-467.
14. Blonde L, Wogen J, Kreilick C, Seymour AA. Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metformin. Diabetes Obes Metab 2003; 5: 424-431.
15. Eucreas [package insert]. Nürnberg, Germany: Novartis Pharma GmbH; 2008.
16. Bosi E, Dotta F, Jia Y, Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009; 11: 506-515.
17. (US) FDA News. FDA issues safety alert on Avandia, May 21, 2007. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/ NEW01636.html. Last accessed on 01 December 2008.
18. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality? A meta-analysis of observational studies. Diabetes Care 2008; 31: 1672-1678.
19. Kothny W, Gimpelewicz CR, Byiers S, Mills D, Fitchet M. Cardiovascular safety profile of vildagliptin, a new DPP-4 inhibitor for the treatment of type 2 diabetes. Poster presented at: European Association for the study Diabetes-44 th Annual Scientific Sessions; September 7-11, 2008; Rome, Italy. Poster P-915.